New hope for stem cell transplant patients: simpler drug combo may reduce severe side effects

NCT ID NCT06252870

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different pre-transplant conditioning plans combined with a single drug combination (cyclophosphamide and methotrexate) to prevent graft-versus-host disease (GVHD) in blood cancer patients receiving a stem cell transplant from a matched donor. About 82 adults aged 18-70 will take part. The goal is to see if this approach can reduce severe GVHD while allowing fewer long-term immune-suppressing drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

CHU Angers
RECRUITING

Angers, France
CHU Brest
RECRUITING

Brest, France
CHU Nantes
RECRUITING

Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.